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UNTIL now, attempts to identify in
tumour cells a selective biochemical differ-
ence which might be susceptible to
selective chemical attack have not been
successful. However, studies have shown
that tumour cells, unlike normal cells,
frequently become resistant to cytotoxic
drugs, and this recognition has led to
the widespread use of multiple drugs in
combination in the treatment of a variety
of human malignant tumours. Combina-
tion schedules are legion and most ofthese
are based on the association of one or
more anti-metabolites with one or more
alkylating agents, often with steroids and
cytotoxic antibiotics and plant extracts.
These schedules have invariably been
derived empirically and, except in a few
instances, little attention has been paid
to the clinical or biochemical pharma-
cology of the component drugs or to
their possible interaction. Moreover,
there has been a blind faith in the syner-
gisms of drugs used in combination with
little concern over possible antagonisms.
Goodman's group first suggested that
tumour resistance to the anti-metabolite
methotrexate might be exploited thera-
peutically (Goodman et al., 1964). They
had observed that tumour cells which
developed resistance to this agent fre-
quently had increased levels of the
enzyme dihydrofolate reductase (Friedkin
et al., 1962). It was therefore suggested
that these cells wouild be selectively
sensitive on the basis of their high
reductase activity to anti-metabolite com-
pounds which were activated by this
enzyme. The homofolates are activated
in this way but their use in this context
has been frustrated by their chemical
instability. Recently, more stable re-
duced homofolate compounds have been
synthesized and preliminary results in
mice bearing leukaemia L1210 indicate
that dihydrohomofolate has greater acti-
vity against a methotrexate-resistant
tumour with high levels of dihydrofolate
reductase than against a methotrexate-
sensitive tumour with normal levels of
the enzyme (Mishra and Mead, 1972).
The results shown by these workers thus
substantiate the principle of an enzyme-
dependent regeneration of a faulty co-
factor being a useful model for obtaining
selective anti-tumour effects.
The investigation of acqutired drug
resistance in animal tumours has led to
the recognition ofseveral possible mechan-
isms for resistance to any particular
drug. The difficulty of obtaining suitable
material for study from human tumours
has prevented detailed investigation.
However, Steuart and Burke (1971) have
recently reported that cytidine deaminase
activity is increased in leukaemic cells
of patients whose disease has become
resistant to treatment witlh cytosiine
arabinoside. This finding, if confirmed,
identifies a poteintially exploitable charac-
teristic of humain leukaemic cells. In
normal human tissue cytidine deaminase
activity is not great ancd it is perhaps
for this reason that 5-fluorocytosine, aTHE EMERGENCE OF DRUG RESISTANCE IN TUMOURS
drug which is activated by deamination
is, in general, a non-toxic agent (Koechlin
et al., 1966). This drug, which was
originally synthesized by Heidelberger et
al. (1957) and discarded as it had no
useful anti-tumour effects, has in the
last few years been found to be an
effective anti-fungal agent. It seems
clear that the toxicity of 5-fluorocytosine
against fungi is due to their having an
active deaminase which converts 5-fluoro-
cytosine to 5-fluorouracil. This latter
agent, following its metabolism to 5-fluoro-
deoxyuridine monophosphate, is an inhi-
bitor of thymidylate synthetase. Thus,
it is believed that the selective toxicity
of 5-fluorocytosine in fungi and not in
normal human cells is a consequence of
the fungi possessing an enzyme which
activates the drug to a lethal com-
pound.
5-fluorocytosine has been used widely
for the treatment of fungal disease during
the past few years (Fass and Perkins,
1971). Adverse reactions reported during
5-fluorocytosine treatment have been rare,
although one or two patients have become
severely thrombocytopenic and neutro-
penic while taking the drug. No satis-
factory explanation of these toxicities
has been suggested, nor is it apparent
that these effects were seen in patients
with leukaemia who had previously been
treated with cytosine arabinoside for
their primary disease.
The recognition that human leukaemic
cells which have become resistant to
cytosine arabinoside may contain in-
creased cytidine deaminase activity (Steu-
art and Burke, 1971) indicates a potential
therapeutic use for 5-fluorocytosine. In
this context, it is reasonable to assume
that the drug would be toxic only in
those cells which contained high de-
aminase activity and that such cells
would be leukaemic.
Preliminary studies in this laboratory
of the cytidine kinase and deaminase
activity of human leukaemic cells have
shown that deaminase activity is increased
in the leukaemic cells of some patients
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who have been treated with cytosine
arabinoside. It is planned to treat
patients whose leukaemic cells have high
cytidine deaminase activity with 5-fluoro-
cytosine in the hope that this drug will
be selectively toxic to their leukaemic
clone of cells. It has also been observed
that the cytidine kinase activity may be
increased in cells with high deaminase
activity, and it thus remains to be shown
that the high deaminase activity reported
by Steuart and Burke (1971) is more
than a non-specific indication of an
immature cell population being selected
by chemotherapy, rather than a particular
mechanism ofresistance.
It is widely recognized in cancer
chemotherapy clinics that while tumour
cells may become resistant to repeated
courses of cytotoxic therapy normal
marrow and gut lining cells appear to
maintain their sensitivity. It is this
factor which usually limits the scale of
chemotherapy in patients with drug-
resistant tumours, since the large doses
of cytotoxic drugs which may be required
to overcome resistance are not tolerated
by the normal host tissues. However,
this therapeutic impasse has specific
chemotherapeutic possibilities in a very
general sense also. This derives from
the principle of therapeutic " rescue "
which has been used widely during the
last few years, particularly with the
antifolate drug, methotrexate. The prin-
ciple of this approach, as currently
practised, is that an agent which damages
rapidly proliferating cells, leading to cell
death, may have less drastic effects in
more slowly proliferating cells provided
the duration of drug exposure is short
(Bruce, Meeker and Valeriote, 1966).
Methotrexate, by blocking the enzyme
dihydrofolate reductase, deprives cells
of the reduced folate co-factors which
are required for DNA synthesis (Osborne,
Freeman and Huennekins, 1958). Re-
duced folate (folinic acid) can be ad-
ministered after a 24-36 hour metho-
trexate infusion, and this will immediately
restore the folate pools in cells which
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have not been irreparably damaged by
the folate depletion. Experience has in-
dicated that this population of cells is
composed mainly of normal and not
tumour cells. Using this approach, im-
pressive cancer therapeutic successes have
been reported (Capizzi et al., 1970;
Djerassi et al., 1972).
In the case of methotrexate-resistant
tumour cells and sensitive marrow and
gut cells, methotrexate therapy will in-
hibit DNA synthesis in the normal cells
but have little effect on the resistant
tumour cells. In this situation, it seems
possible that resistant tumour cells will
be selectively sensitive to agents which
lethally damage cells undergoing DNA
synthesis. Thus, prior administration of
a methotrexate infusion would protect
normal cells from the lethal effects of
subsequently administered cytosine arabi-
noside, and the cytosine arabinoside
would be selectively toxic to the resistant
cells synthesizing DNA. Following 24-36
hours ofmethotrexate infusion, thenormal
marrow and gut cells would be " rescued"
with folinic acid.
Thus, the emergence ofdrug resistance
in tumours may be turned to therapeutic
advantage. It is clearly important that
the mechanisms of cytotoxic drug action
and resistance in human tumour cells
should be studied, not only so that drugs
may be administered in rational com-
bination schedules, but also so that
possible selective advantage may be
taken of the potentiality of tumour cells
to develop alternate metabolic paths.
M. H. N. Tattersall is a Medical
Research Council Clinical Research Fel-
low.
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